DV
Dividend Vision

IDXG — Interpace Biosciences Inc

Interpace Biosciences Inc (IDXG)

Its deepest 1-year drawdown was 41.7%.

Interpace Biosciences provides molecular diagnostic tests and pathology services for evaluating cancer risk in the United States, offering products including ThyGeNEXT and ThyraMIR v2 to assess thyroid nodules for malignancy risk and identify oncogenic mutations. The company does not currently distribute dividends. Interpace Biosciences serves physicians, cancer centers, clinics, laboratories, pathology groups, and hospitals.

IDXG key facts

Asset type
Stock
Asset class
Equity
Inception date
05/20/1998
Last close
$1.66
Market cap
$46,260,508
Average volume
21700.0
Payment date
01/15/2020
Beta
0.606
Payout ratio
0.0
P/E ratio
1.8556
Forward P/E
7.1582
EPS
$0.90